A Phase 4 interventional study of Memantine (once daily) and Memantine (twice daily) in Alzheimer Dementia (AD), sponsored by H. Lundbeck A/S. Completed at 6 sites in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2019-03-14.
Sponsored by H. Lundbeck A/S · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing memantine in Alzheimer Disease — 1 open to participants now, 2 under way, none of them phase 3. Memantine · Alzheimer Disease.
Among the 34 studies testing memantine in Alzheimer Disease, this one is the 20th largest by enrollment, is the only one that started in 2015, is one of 21 in phase 4, and was the 27th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →1 of the 34 studies testing memantine in Alzheimer Disease is open now, in 1 country. Recruiting first, the newest first:
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–32
By country, each count listing its studies:
Memantine: first FDA approval 2003 (NAMENDA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 9 · Phase 4 21
First in 2003; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 90 across the 34 interventional studies. Of the 28 that completed or were terminated, 15 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 34 have an industry lead sponsor. The 10 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
16 studies in Alzheimer Disease by H. Lundbeck A/S: none open now, none under way, none of them phase 3. Of 16 finished, 8 (50%) have results posted.
Among the 16 studies in Alzheimer Disease by H. Lundbeck A/S, this one is the 11th largest by enrollment, is one of 3 that started in 2015, is one of 2 in phase 4, and was the 12th registered.
H. Lundbeck A/S’s Alzheimer Disease studies by the year they started, since 2003.
1 of the studies testing memantine in Alzheimer Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05063851University of VirginiaThe Use of Memantine for Prevention of Alzheimer's Disease | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies testing memantine in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among H. Lundbeck A/S’s 16 in Alzheimer Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluation of the safety and tolerability of a 20 mg once daily dose of memantine compared with 10 mg given twice daily in patients with dementia of Alzheimer's type and MMSE range 5-18.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion and exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Memantine 20 mg once daily, tablets, orally AND Placebo tablets once daily, orally
Drug: Memantine (once daily)
Memantine 10 mg twice daily, tablets, orally AND Placebo tablets twice daily, orally
Drug: Memantine (twice daily)
Also known as: Lu 00-800, Ebixa ®, Ebix ®
Also known as: Lu 00-800, Ebixa ®, Ebix ®
Adverse Events
Number of patients who reported adverse events
Time frame: baseline to week 16 (end of study)
ADCS - CGIC Score at Week 12
The Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) is a semi-structured interview designed to assess clinically relevant changes in patients with Alzheimer's disease. Items in the ADCS-CGIC interview provide general information, and information about cognition, behaviour, social and daily functioning. Responses to ADCS-CGIC interview result in a global clinical judgement of severity (at baseline) and clinically relevant change at subsequent visits. Severity rated at baseline is only used for reference. The severity at baseline is rated on a 7-point Likert-type scale from 1(normal, not ill at all) to 7 (among the most extremely ill patients). The ADCS-CGIC relevant change is rated on a 7-point Likert-type scale from 1 (marked improvement) to 7 (marked worsening).
Time frame: ADCS - CGIC score at Week 12
| Milestone | Memantine (Once Daily) | Memantine (Twice Daily) |
|---|---|---|
| Started | 30 | 32 |
| Completed | 28 | 29 |
| Not completed | 2 | 3 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Administrative reason(s) | 0 | 1 |
Number of patients who reported adverse events
| Participants | Memantine (Once Daily) | Memantine (Twice Daily) |
|---|---|---|
| Adverse Events | 15 | 16 |
The Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) is a semi-structured interview designed to assess clinically relevant changes in patients with Alzheimer's disease. Items in the ADCS-CGIC interview provide general information, and information about cognition, behaviour, social and daily functioning. Responses to ADCS-CGIC interview result in a global clinical judgement of severity (at baseline) and clinically relevant change at subsequent visits. Severity rated at baseline is only used for reference. The severity at baseline is rated on a 7-point Likert-type scale from 1(normal, not ill at all) to 7 (among the most extremely ill patients). The ADCS-CGIC relevant change is rated on a 7-point Likert-type scale from 1 (marked improvement) to 7 (marked worsening).
| units on a scale | Memantine (Once Daily) | Memantine (Twice Daily) |
|---|---|---|
| ADCS - CGIC Score at Week 12 | 3.92 ± 0.14 | 3.60 ± 0.14 |
Collected over Baseline to week 16 (end of study). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Memantine (Once Daily) | — | 0/30 (0%) | 6/30 (20%) |
| Memantine (Twice Daily) | — | 1/32 (3.1%) | 2/32 (6.3%) |
| Event | Memantine (Once Daily) | Memantine (Twice Daily) |
|---|---|---|
| Spinal compression fractureInjury, poisoning and procedural complications | 0/30 | 1/32 |
| Event | Memantine (Once Daily) | Memantine (Twice Daily) |
|---|---|---|
| HypertensionVascular disorders | 2/30 | 0/32 |
| Sinus bradycardiaCardiac disorders | 2/30 | 0/32 |
| White blood cell count decreasedInvestigations | 2/30 | 0/32 |
| Urinary incontinenceRenal and urinary disorders | 0/30 | 2/32 |
| Age, Continuous(years) | Memantine (Once Daily) | Memantine (Twice Daily) | Total |
|---|---|---|---|
| Mean | 69.1 ± 9.3 | 70.3 ± 8.1 | 69.7 ± 8.6 |
| Sex: Female, Male(Participants) | Memantine (Once Daily) | Memantine (Twice Daily) | Total |
|---|---|---|---|
| Female | 17 | 17 | 34 |
| Male | 13 | 15 | 28 |
| Race/Ethnicity, Customized(Participants) | Memantine (Once Daily) | Memantine (Twice Daily) | Total |
|---|---|---|---|
| Asian | 30 | 32 | 62 |
| MMSE Total Score(units on a scale) | Memantine (Once Daily) | Memantine (Twice Daily) | Total |
|---|---|---|---|
| Mean | 11.4 ± 4.2 | 11.4 ± 4.5 | 11.4 ± 4.3 |
| Modified Hachinski Ischemia Total Score(units on a scale) | Memantine (Once Daily) | Memantine (Twice Daily) | Total |
|---|---|---|---|
| Mean | 1.6 ± 1.2 | 1.8 ± 0.9 | 1.7 ± 1.0 |
| Duration of Alzheimer's Disease(years) | Memantine (Once Daily) | Memantine (Twice Daily) | Total |
|---|---|---|---|
| Mean | 2.1 ± 1.9 | 2.3 ± 1.9 | 2.2 ± 1.9 |
The record gives a start of Oct 2015, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2019, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Memantine